目的 探究定坤丹联合戊酸雌二醇治疗围绝经期综合征的临床疗效。方法 选取2013年5月-2016年5月攀枝花市妇幼保健院接受诊治的围绝经期综合征患者82例，随机分为对照组和治疗组，每组各41例。对照组患者口服戊酸雌二醇片，2片/d，治疗21 d为1个周期。治疗组患者在对照组的基础上口服定坤丹，每日早晚各1/2丸，连续3个月为1个疗程。两组均治疗3个月。治疗后，观察两组的临床疗效，并比较两组卵泡刺激素（FSH）和雌二醇（E₂）水平，焦虑自评量表（SAS）、抑郁自评量表（SDS）、绝经期生存质量量表（MENQOL）和Greene更年期症状量表评分。结果 治疗后，对照组和治疗组的总有效率分别为87.8%和97.6%，两组总有效率比较差异有统计学意义（P<0.05）。治疗后，两组FSH水平明显降低，E₂水平显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组激素水平的改善明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组SAS、SDS、MENQOL和Greene评分均降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组上述量表评分明显低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 定坤丹联合戊酸雌二醇治疗围绝经期综合征疗效显著，可维持围绝经期妇女正常的激素水平，减轻不良症状，具有一定的推广应用价值。

Objective To explore the clinical efficacy of Dingkundan combined with estradiol valerate in treatment of perimenopause syndrome. Methods Patients (82 cases) with perimenopause syndrome in Panzhihua Women and Children's Hospital from May 2013 to May 2016 were randomly divided into control and treatment groups, and each group had 41 cases. Patients in the control group were po administered with Estradiol Valerate Tablets, 2 tablets/d, and 21 d was one cycle. Patients in the treatment group were po administered with Dingkundan, 1/2 pill in the morning and evening. Three months were as one course. Two groups were both treated for 3 months. After treatment, the clinical efficacies were evaluated, and follicle stimulating hormone (FSH) and estradiol (E₂) levels, and self-rating anxiety scale (SAS), self-rating depression scale (SDS), menopause-specific quality of life questionnaire (MENQOL), and Greene menopausal symptoms scale in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 87.8% and 97.6%, respectively, and there was difference between two groups (P<0.05). After treatment, FSH level in two groups was significantly decreased, while E₂ level in two groups was significantly increased, and the difference was statistically significant in the same group (P<0.05). And the hormone levels in the treatment group were improved more than those in the control group, with significant difference between two groups (P<0.05). After treatment, SAS, SDS, MENQOL, and Greene scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And these scores in the treatment group were improved more than those in the control group, with significant difference between two groups (P<0.05). Conclusion Dingkundan combined with estradiol valerate has clinical curative effect in treatment of perimenopause syndrome, can maintain normal hormone levels in perimenopausal women and reduce adverse symptoms, which has a certain clinical application value.